Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer

TAKASHI HIGUCHI1,2,3, QINGHONG HAN1, NORIHIKO SUGISAWA1,2, JUN YAMAMOTO1,2, NORIO YAMAMOTO3, KATSUMI HAYASHI3, HIROAKI KIMURA3, SHINJI MIWA3, KENTARO IGARASHI3, MICHAEL BOUVET2, SHREE RAM SINGH4, HIROYUKI TSUCHIYA3 and ROBERT M. HOFFMAN1,2

1AntiCancer, Inc., San Diego, CA, U.S.A.; 2Department of Surgery, University of California, San Diego, CA, U.S.A.; 3Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan; 4Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A.

Abstract. Background/Aim: Cancers are selectively sensitive to methionine (MET) restriction (MR) due to their addiction to MET which is overused for elevated methylation reactions. MET addiction of cancer was discovered by us 45 years ago. MR of cancer results in depletion of S-adenosylmethionine (SAM) for transmethylation reactions, resulting in selective cancer-growth arrest in the late S/G2-phase of the cell cycle. The aim of the present study was to determine if blockade of the MET-methylation axis is a highly-effective strategy for cancer chemotherapy. Materials and Methods: In the present study, we demonstrated the efficacy of MET-methylation-axis blockade using MR by oral-recombinant methioninase (o-rMETase) combined with decitabine (DAC), an inhibitor of DNA methylation, and an inhibitor of SAM synthesis, cycloleucine (CL). We determined a proof-of-concept of the efficacy of the MET-methylation-axis blockade on a recalcitrant undifferentiated/unclassified soft-tissue sarcoma (USTS) patient-derived orthotopic xenograft (PDOX) mouse model. Results: The o-rMETase-CL-DAC combination regressed the USTS PDOX with extensive cancer necrosis.

Conclusion: The new concept of combination MET-methylation-axis blockade is effective and can now be tested on many types of recalcitrant cancer.

Methionine (MET) addiction (1-14) is a fundamental and general hallmark of cancer discovered by us 45 years ago (3). MET addiction is observed in the clinic where the high demand for MET by cancers, results in a strong signal from [11C]-MET-PET imaging (2). MET addiction involves elevated MET flux in cancer cells (3-6) due to excess levels of transmethylation reactions (4), known as the Hoffman effect (7). MET addiction is a general phenomenon in cancer and a crucial target for cancer therapy by MET restriction (MR) which results in depletion of free MET and S-adenosylmethionine (SAM) (5, 6, 10) and selective S/G2-phase cell-cycle arrest in cancer cells (11-13). MET addiction is tightly linked to other hallmarks of cancer (14).

Recombinant methioninase (rMETase) targets MET addiction of cancer cells by severely depleting the sources of cellular MET (1, 15). We demonstrated the effectiveness of oral administration of rMETase (o-rMETase) on many types of chemotherapy-resistant cancers with patient derived orthotopic xenograft (PDOX) mouse models (15-19).

Decitabine [5-aza-2′-deoxycytidine, (DAC)], which is in clinical use for myelodysplastic syndrome and leukemia treatment, is a DNA-methylation inhibitor that incorporates irreversibly into DNA and causes DNA hypomethylation (20, 21). The efficacy of DAC alone for cancer treatment was unsatisfactory (22-26). We recently reported that the combination of o-rMETase and DAC inhibited a recalcitrant undifferentiated/unclassified soft-tissue sarcoma (USTS) PDOX model (27). Cycloleucine (CL), an inhibitor of MET adenosyltransferase-2A (MAT2A), which catalyzes SAM synthesis from MET and ATP, has been shown to lower intracellular SAM (28-30).
Soft-tissue sarcoma is a rare cancer which arises from mesenchymal cells (31). Chemotherapy is used in combination with surgery to treat soft-tissue sarcoma (32). Doxorubicin (DOX) has been used for soft-tissue sarcoma for the past 40 years, but with limited efficacy (31, 33, 34). USTS, formerly known as malignant fibrous histiocytoma, is a frequent type of soft-tissue sarcoma seen in the middle-aged and the elderly (35). The outcome of USTS is usually unsatisfactory when the tumor is resistant to DOX (33, 34).

Based on MET addiction due to excess transmethylation reactions, we hypothesized that CL could be combined with o-rMETase and DAC for MET and methylation blockade for highly effective therapy of the USTS PDOX model. The present report is a proof-of-concept that MET-methylation-axis blockade can effectively target a recalcitrant cancer.

Materials and Methods

Mice. Athymic nude mice, at 4-6 weeks of age, were from AntiCancer Inc. (San Diego, CA, USA). An IACUC protocol was approved for the present study following the principles and procedures described in the National Institutes of Health Guide for the Care and Use of Animals under Assurance Number A3873-1 (36). All surgical procedures were conducted under appropriate anesthesia and analgesia (36).

Patient-derived tumor. A fresh surgical sample from the USTS patient not otherwise specified (NOS), who underwent surgery at UCLA, was previously brought to AntiCancer, Inc. for establishment in nude mice (34). The patient provided written informed consent with UCLA IRB#10-001857 approval (34).

Surgical orthotopic implantation (SOI). A single tumor fragment (2-3 mm), harvested from a subcutaneously-grown tumor in nude mice, was implanted into the nude-mouse biceps, to establish USTS PDOX models, as described in our previous reports (27, 31).

Treatment protocols. The PDOX mouse models (n=6/group) were treated as follows (Figure 1): G1, Untreated control; G2, CL (50 mg/kg, intraperitoneal injection, twice per week); G3, o-rMETase (50 units/mouse, oral gavage, twice per day); G4, DOX (3 mg/kg, intraperitoneal injection, once per week); G5, CL+ DAC (50 mg/kg, intraperitoneal injection, once per day); G6, o-rMETase + CL + DAC. Treatment was initiated after all tumors reached at least 100 mm³.

Histological analysis. The procedures for fixation, sectioning, deparaffinizing, and staining of harvested tumor samples were conducted as described previously (37).

Results

MET-methylation-axis blockade regressed the sarcoma PDOX. Only the MET-methylation-axis blockade regressed the recalcitrant USTS PDOX tumor (p<0.001). o-rMETase alone (p=0.03), the CL-DAC combination (p=0.003), as well as the rMETase-CL-DAC combination MET-methylation-axis blockade (p<0.001) significantly inhibited the USTS PDOX tumor compared to the control. The o-rMETase-CL-DAC combination had significantly better efficacy than the other treatments: vs. CL alone (p=0.001); vs. o-rMETase alone (p=0.007); or vs. DOX alone (p=0.03). CL alone did not inhibit the tumor (p=0.44) (Figures 2 and 3).

The combination MET-methylation-axis blockade caused extensive necrosis in the sarcoma PDOX. Only the PDOX tumors treated with the MET-methylation-axis blockade had extensive tumor necrosis. The control USTS PDOX tumor had a high cell density comprising atypical spindle-shaped cancer cells (Figure 4A, A’). USTS PDOX tumors treated with CL alone (Figure 4B, B’), o-rMETase alone (Figure 4C, C’), DOX alone (Figure 4D, D’), and the CL-DAC (Figure 4E, E’) combination showed viable pleomorphic cancer cells; however these groups had less viable cancer cells than the untreated control. The o-rMETase-CL-DAC combination induced widespread necrosis (Figure 4F) with non-viable cancer cells and stroma replaced by degenerative scars (Figure 4F’). These results further showed the efficacy of MET-methylation-axis blockade.

Effect of treatment on body weight. Only treatments containing CL caused body-weight loss: CL alone (p=0.001), the CL-DAC combination (p=0.001), and the o-rMETase-CL-DAC combination (p=0.001) (Figure 5).

Discussion

MET addiction of cancer is due to excess and aberrant transmethylation reactions, that consume much larger than
normal amounts of MET (3-6, 10). Lowered DNA methylation is a hallmark of cancer cells, originally discovered in our laboratory (39), and may be due to diversion of methyl groups to other substances such as histones (please see below). Several demethylating agents have been used for cancer treatment (21, 40) including DAC, as well as azacitidine which has been used to treat myelodysplastic syndrome (41). These inhibitors cause hypomethylation of DNA, but had limited efficacy in the clinic (25, 40, 41). In our recent study, a DNA hypomethylating drug alone did not inhibit a USTS-
PDOX, but o-rMETase combined with a DNA-hypomethylating drug arrested the PDOX tumors and decreased the cancer-cell density, suggesting the combination of rMETase and a DNA hypomethylating agent could be effective to inhibit tumor growth (27, 37).

In order to enhance MR, we examined the efficacy of the SAM-synthesis inhibitor, CL (30) along with o-rMETase and DAC in the present study. SAM, which plays an important role in transmethylation reactions in all cells, is synthesized from MET by MAT2A (28). CL inhibits SAM synthesis by inhibiting
MAT2A, resulting in hypomethylation in the tumor and may increase the DNA hypomethylation efficacy of DAC (28, 30). CL may be too toxic at the current dose, leading to mouse body-weight loss. Future studies will examine the most effective non-toxic dose of CL for optimal MET-methylation-axis blockade.

o-rMETase has now shown clinical efficacy in a pilot study (42). Recently, a study showing efficacy of a human enzyme engineered to be a METase was published, stating it is superior to the bacterial METase used in the present study, due to its long half-life in the circulation (43). However due to the hardiness of the bacterial enzyme to survive stomach acidity, it could be dosed orally as shown in the present and previous studies (15-19, 27, 37), giving it superiority over the injected engineered human METase. Bacterial o-rMETase is much superior to injected bacterial rMETase (44). Future studies will include determination of the efficacy of MET-methylation-axis blockade on the major cancer types in PDOX models. Recent papers have come out claiming novelty on MET addiction (45, 46), about which we published long ago (2-12, 47-50). Targeting a central aspect of metabolism such as MET and methylation has far more potential for cancer therapy than targeting peripheral metabolism, despite claims of “metabolic dependence” (51). MET addiction, discovered by us, is found in all cancer types and is linked to other hallmarks of cancer (14). All cancer types tested are sensitive to MR, whether by methionine-free media (8, 52), diet (47-49) or methioninase (15-19, 27, 37). A recent study in our laboratory (53) has demonstrated that the combination of o-rMETase, CL and azacitidine arrested a pancreatic cancer PDOX, further demonstrating that blocking the MET-methylation-axis is highly-effective chemotherapy against recalcitrant cancers and has clinical potential. Other recent studies from our laboratory have shown that excess transmethylation that causes MET addiction in cancer cells results in hypermethylation of histone H3 lysine marks (54, 55). These facts suggest MET addiction may be the very basis of cancer (3). Orthotopic mouse models of sarcoma (31) such as that used in the present study, are clinically relevant, unlike ectopic subcutaneous sarcoma mouse models (56). Recently, more potent inhibitors of MAT2A, which is regulated differently in normal and cancer cells (50), have been developed (57) and may be used in MET-transmethylation-axis blockade, which directly targets the elevated flux of methionine in cancer cells, termed the Hoffman effect (58).

**Conflicts of Interest**

The Authors declare no competing interests.

**Authors’ Contributions**

Conception and design: TH and RMH. Acquisition of data: TH, QH, NS, JY, NY, KH, HK, SM, and KI. Analysis and interpretation of data: TH, NY, KH, HK, SM, MB, HT, and RMH. Writing, review, and/or revision of the manuscript: TH, HT, SRS, and RMH.

**Acknowledgements**

This paper is dedicated to the memory of AR Moossa, MD, Sun Lee, MD, Professor Jiaxi Li, and Masaki Kitajima, MD.

**References**

1. Hoffman RM: Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther 15(1): 21-31, 2015. PMID: 25439528. DOI: 10.1517/14712598.2015.963050
2. Aki T, Nakayama N, Yonezawa S, Takenaka S, Miwa K, Asano Y, Shinoda J, Yano H and Iwama T: Evaluation of brain tumors using dynamic 11C-methionine-PET. J Neurooncol 109(1): 115-122, 2012. PMID: 22528799. DOI: 10.1007/s11060-012-0873-9
3. Hoffman RM and Erbe RW: High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotropic for methionine. Proc Natl Acad Sci USA 79(5): 1523-1527, 1976. PMID: 179090. DOI: 10.1073/pnas.79.14.4248
4. Stern PH and Hoffman RM: Elevated overall rates of transmethylation in cell lines from diverse human tumors. Proc Natl Acad Sci USA 73(5): 1523-1527, 1976. PMID: 179090. DOI: 10.1073/pnas.73.5.1523
5. Kaiser P: Methionine dependence of cancer. Biomolecules 10(4): 568, 2020. PMID: 32276408. DOI: 10.3390/biom10040568
on rat leukemia. Cancer Lett 41(3): 295-305, 1988. PMID: 3409208. DOI: 10.1016/0304-3835(88)90291-1

30 Kroes AC, Lindemans J and Abels J: Synergistic growth inhibiting effect of nitrous oxide and cycloleucine in experimental rat leukemia. Br J Cancer 50(6): 793-800, 1984. PMID: 6980876. DOI: 10.1038/bj.1984.258

31 Igarashi K, Kawaguchi K, Murakami T, Miyake K, Kiyuna T, Miyake M, Hiroshima Y, Higuchi T, Oshiro H, Nelson SD, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Singh SR, Tsuichiya H and Hoffman RM: Patient-derived orthotopic xenograft models of sarcoma. Cancer Lett 469: 332-339, 2020. PMID: 31639427. DOI: 10.1016/j.canlet.2019.10.028

32 Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K and Tsuichiya H: Therapeutic targets for bone and soft-tissue sarcomas. Int J Mol Sci 20(1): 170, 2019. PMID: 30621224. DOI: 10.3390/ijms20010170

33 Kawaguchi K, Igarashi K, Miyake K, Kiyuna T, Miyake M, Singh AS, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Unno M, Singh SR, Eilber FC and Hoffman RM: Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. J Drug Target 27(2): 211-216, 2019. PMID: 30024282. DOI: 10.1080/1061186X.2018.1499748

34 Kawaguchi K, Igarashi K, Miyake K, Tsuchiya M, Hayashi K, Takeuchi A, Igarashi K, Murakami T, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Singh AS, Unno M, Eilber FC and Hoffman RM: Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. Cell Cycle 17(5): 627-633, 2018. PMID: 29384032. DOI: 10.1080/15384101.2017.1421876

35 Fletcher CD: Undifferentiated sarcomas: what to do? And does it matter? A surgical pathology perspective. Ultrastruct Pathol 32(2): 31-36, 2008. PMID: 18446665. DOI: 10.1080/01913120801896945

36 Higuchi K, Miyake K, Oshiro H, Sugisawa N, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Chawla SP, Bouvet M, Singh SR, Tsuichiya H and Hoffman RM: Trabectedin and irrinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model. Biochem Biophys Res Commun 513(2): 326-331, 2019. PMID: 30955860. DOI: 10.1016/j.bbrc.2019.03.191

37 Higuchi T, Sugisawa N, Yamamoto J, Oshiro H, Han Q, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Tan Y, Kuchipudi S, Bouvet M, Singh SR, Tsuichiya H and Hoffman RM: The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. Cancer Chemother Pharmacol 85(2): 285-291, 2020. PMID: 31705268. DOI: 10.1007/s00280-019-03986-0

38 Tan Y, Xu M, Tan X, Tan X, Wang X, Saikawa Y, Nagahama T, Sun X, Lenz M and Hoffman RM: Overexpression and large-scale production of recombinant L-methionine-alpha-deaminogamma-mercaptomethanelysine for novel anticancer therapy. Protein Expr Purif 9(2): 233-245, 1997. PMID: 9056489. DOI: 10.1006/prep.1996.0700

39 Diala ES and Hoffman RM: Hypomethylation of HeLa cell DNA and the absence of 5-methylcytosine in SV40 and adenovirus (type 2) DNA: analysis by HPLC. Biochem Biophys Res Commun 107(1): 19-26, 1982. PMID: 6289818. DOI: 10.1016/0006-291x(82)91663-1

40 Kulis M and Esteller M: DNA methylation and cancer. Adv Genet 70: 27-56, 2010. PMID: 20920744. DOI: 10.1016/B978-0-12-380866-0.60002-2

41 Cataldo VD, Cortes J and Quintas-Cardama A: Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther 9(7): 875-884, 2009. PMID: 19589026. DOI: 10.1586/era.09.61

42 Han Q, Tan Y and Hoffman RM: Oral dosing of recombinant methioninase is associated with a 70% drop in PSA in a patient with bone-metastatic prostate cancer and 50% reduction in circulating methioninase in a high-stage ovarian cancer patient. Anticancer Res 40: 2813-2819, 2020. PMID: 32366428. DOI: 10.21873/anticanres.14254

43 Lu WC, Saha A, Yan W, Garrison K, Lamb C, Pandey R, Irani S, Lodi A, Lu X, Tiziani S, Zhang YJ, Georgiou G, DiGiovanni J and Stone E: Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity. Proc Natl Acad Sci USA 117(23): 13000-13011, 2020. PMID: 32349518. DOI: 10.1073/pnas.1917362117

44 Wang Y, Yang J, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C, Zhang D, Zhang Y, Li S, Sun X, Tan Y, Yagi S, Frenkel EP and Hoffman RM: PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 64(18): 6673-6678, 2004. PMID: 15374983. DOI: 10.1158/0008-5472.CAN-04-1822

45 Wang Z, Yip LY, Lee JHJ, Wu Z, Chew HY, Chong PKW, Teo CC, Ang HY, Peh KLE, Yuan J, Ma S, Choo LSK, Basri N, Jiang X, Yu Q, Hillmer AM, Lim WT, Lim TKH, Takano A, Tan EH, Tan DSW, Ho YS, Lim B and Tan WL: Methioninase is a metabolic dependency of tumor-initiating cells. Nat Med 25(5): 825-37, 2019. PMID: 31061538. DOI: 10.1038/s41591-019-0423-5

46 Gao X, Sanderson SM, Dai Z, Reid MA, Cooper DE, Lu M, Lu M, Richie JP Jr, Ciccarella A, Calcagnotto A, Mikhail PG, Mentch SJ, Liu J, Ables G, Kirsch DG, Hsu DS, Nichenametla SN and Locasale JW: Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature 572(7769): 397-401, 2019. PMID: 31367041. DOI: 10.1038/s41586-019-1437-3

47 Hoshiya Y, Guo H, Kubota T, Inada T, Asanuma F, Yamada Y, Koh J, Kitajima M and Hoffman RM: Human tumors are methionine dependent in vivo. Anticancer Res 15(3): 717-718, 1995. PMID: 7645948.

48 Hoshiya Y, Kubota T, Matsuzaki SW, Kitajima M and Hoffman RM: Methionine starvation modulates the efficacy of cisplatin on human breast cancer in nude mice. Anticancer Res 16(6B): 3515-3517, 1996. PMID: 9042214.

49 Hoshiya Y, Kubota T, Inada T, Kitajima M and Hoffman RM: Methionine-depletion modulates the efficacy of 5-fluorouracil in human gastric cancer in nude mice. Anticancer Res 17(6D): 4371-4375, 1997. PMID: 9494535.

50 Jacobsen SJ, Hoffman RM: and Erbe RW: Regulation of methionine adenosyltransferase in normal diploid and simian virus 40-transformed human fibroblasts. J Natl Cancer Inst 65(6): 1237-1244, 1980. PMID: 6253712.

51 Chen CC, Li B, Millman SE, Chen C, Li X, Morris JP 4th, Mayle A, Ho YJ, Loizou E, Liu H, Qin W, Shah H, Violante S, Cross JR, Lowe SW and Zhang L: Vitamin B6 addiction in acute
myeloid leukemia. Cancer Cell 37(1): 71-84.e7, 2020. PMID: 31935373. DOI: 10.1016/j.ccell.2019.12.002

52 Stern PH and Hoffman RM: Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 76(4): 629-639, 1986. PMID: 3457200. DOI: 10.1093/jnci/76.4.629

53 Sugisawa N, Yamamoto J, Han Q, Tan Y, Tashiro Y, Nishino H, Inubushi S, Hamada K, Kawaguchi K, Unno M, Bouvet M and Hoffman RM: Triple-methyl blockade with recombinant methioninase, cycloleucine, and azacitidine arrests a pancreatic cancer patient-derived orthotopic xenograft model. Pancreas 50(1): 93-98, 2021. PMID: 33370029. DOI: 10.1097/MPA.00000000000001709

54 Yamamoto J, Han Q, Inubushi S, Sugisawa N, Hamada K, Nishino H, Miyake K, Kumamoto T, Matsuyama R, Bouvet M, Endo I and Hoffman RM: Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells. Biochem Biophys Res Commun 533(4): 1034-1038, 2020. PMID: 33019978. DOI: 10.1016/j.bbrc.2020.09.108

55 Yamamoto J, Inubushi S, Han Q, Tashiro Y, Sun Y, Sugisawa N, Hamada K, Nishino H, Aoki Y, Miyake K, Matsuyama R, Bouvet M, Endo I and Hoffman RM: Cancer-specific overmethylation of histone H3 lysines is necessary for methionine addiction and malignancy. bioRxiv, 2020. DOI: 10.1101/2020.12.04.412437

56 Marchetto A, Ohmura S, Orth MF, Knott MML, Colombo MV, Arrigoni C, Bardinet V, Saucier D, Wehweck FS, Li J, Stein S, Gerke JS, Baldauf MC, Musa J, Dallmayer M, Romero-Pérez L, Hölting TL, Amatruda JF, Cossartizza A, Henssen AG, Kirchner T, Moretti M, Cidre-Aranaz F, Sannino G and Grünewald TGP: Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma. Nat Commun 11(1): 2423, 2020. PMID: 32415069. DOI: 10.1038/s41467-020-16244-2

57 Kalev P, Hyer ML, Gross S, Konteatis Z, Chen CC, Fletcher M, Lein M, Aguado-Fraile E, Frank V, Barnett A, Mandley E, Goldford J, Chen Y, Sellers K, Hayes S, Lizotte K, Quang P, Tuncay Y, Clasquin M, Peters R, Weier J, Simone E, Murtie J, Liu W, Nagaraja R, Dang L, Sui Z, Biller SA, Travins J, Marks KM and Marjon K: MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell 1535-6108(20):30658-9, 2021. PMID: 33450196. DOI: 10.1016/j.ccell.2020.12.010 [Epub ahead of print].

58 Lauinger L and Kaiser P: Sensing and signaling of methionine metabolism. Metabolites 11(2): 83, 2021. DOI: 10.3390/metabo11020083

Received August 16, 2020
Revised December 31, 2020
Accepted January 19, 2021